

4. Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. *Clin J Gastroenterol.* 2020;13(6):1010-1021.
5. Keighley MR. Gastrointestinal cancers in Europe. *Aliment Pharmacol Ther.* 2003;18 Suppl 3:7-30.
6. Ajani JA, Lee J, Sano T, et al. Gastric adenocarcinoma. *Nat Rev Dis Primers.* 2017;3:17036.
7. Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. *Ann Oncol.* 2009;20(5):885-891.
8. Salem ME, Puccini A, Xiu J, et al. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. *Oncologist.* 2018;23(11):1319-1327.
9. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet.* 2010;376(9742):687-697.
10. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer.* 2015;18(3):476-484.
11. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *NEJM.* 2022;386(5):449-462.
12. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet.* 2021;398(10294):27-40.
13. Kato K, Ajani JA, Doki Y, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. *J Clin Oncol.* 2023;41(4\_suppl):290-290.
14. Ferrara R, Pilotto S, Caccese M, et al. Do immune checkpoint inhibitors need new studies methodology? *J Thorac Dis.* 2018;10(Suppl 13):S1564-s1580.
15. Grassadonia A, Sperduti I, Vici P, et al. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. *J Clin Med.* 2018;7(12).
16. Wu Y, Ju Q, Jia K, et al. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). *Int J Cancer.* 2018;143(1):45-51.
17. Ma J, Yao Y, Tian Y, et al. Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. *Biol Sex Differ.* 2022;13(1):58.
18. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. *Eur J Cancer.* 1997;33(8):1216-1220.
19. Lee SJ, Kim S, Kim M, et al. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. *BMC Cancer.* 2015;15(693).
20. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2019;20(11):1506-1517.
21. Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol.* 2022;33(10):992-1004.
22. Thorén FB, Anderson H, Strannegård Ö. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. *Cancer Immunol Immunother.* 2013;62(10):1547-1551.
23. Derks S, van Laarhoven HWM. Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab-ipilimumab in metastatic gastric and esophageal cancer. *Ther Adv Med Oncol.* 2022;14(17588359221142788).
24. Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. *Nature.* 2022;603(7903):942-948.
25. Janjigian YY, Shitara K, Moehler MH, et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. *J Clin Oncol.* 2023;41(4\_suppl):291-291.
26. Nebot-Bral L, Coutzac C, Kannouche PL, et al. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? *Bull Cancer.* 2019;106(2):105-113.
27. Bristol Myers Squibb. Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma [online]. [cit. 20-8-2023]. Available from: <https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab--Chemotherapy-for-Patients-with-HER2-Negative-Advanced-or-Metastatic-Gastric-Gastroesophageal-Junction-or-Esophageal-Adenocarcinoma/default.aspx>
28. Fassan M, Brignola S, Pennelli G, et al. PD-L1 expression in gastroesophageal dysplastic lesions. *Virchows Arch.* 2020;477(1):151-156.
29. Hagi T, Kurokawa Y, Kawabata R, et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. *Br J Cancer.* 2020;123(6):965-972.
30. Lei M, Siemers NO, Pandya D, et al. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. *Clin Cancer Res.* 2021;27(14):3926-3935.
31. Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. *J Clin Oncol.* 2019;37(11):867-875.
32. Huang T-X, Fu L. The immune landscape of esophageal cancer. *Cancer Commun.* 2019;39(1):79.